%0 Journal Article %A Xia Wei %A Samuel Oxley %A Michail Sideris %A Ashwin Kalra %A Rosa Legood %A Ranjit Manchanda %T 2022-RA-1272-ESGO Cost-effectiveness of risk-reducing surgery for breast and ovarian cancer prevention: a systematic review %D 2022 %R 10.1136/ijgc-2022-ESGO.823 %J International Journal of Gynecologic Cancer %P A383-A384 %V 32 %N Suppl 2 %X Introduction/Background Risk-reducing mastectomy (RRM) and salpingo-oophorectomy (RRSO) are the gold standard preventative strategies for women at high-risk of breast cancer (BC)/ovarian cancer (OC). Risk-reducing early-salpingectomy followed by delayed-oophorectomy (RRESDO) is being trialled as an alternative to RRSO. Opportunistic bilateral salpingectomy (OBS) during gynaecological surgery has been proposed as a potential approach to prevent OC in general population. We performed a systematic review of the published evidence on cost-effectiveness of RRM/RRSO/RRESDO for BC/OC prevention in intermediate/high-risk women, and OBS in baseline-risk.Methodology We searched major databases to December 2021. We included economic evaluation studies reporting on cost-effectiveness/cost-utility outcomes in women at high-risk of BC/OC undergoing RRM/RRSO/RRESDO, or baseline OC risk undergoing OBS.Results Our search yielded 5801 citations; 22 studies were included. Eight studies concluded that RRM/RRSO individually or in combination were cost-effective compared to surveillance/no surgery for unaffected BRCA1/2 carriers, while one study found that RRESDO was cost-effective. Two studies on women at low/intermediate OC-risk specified that RRSO was cost-effective at OC lifetime risks of ≥4% (pre-menopausal) and ≥5% (post-menopausal women). These results were partially sensitive to initial age, uptake rates, cancer risk-reduction, and disutility following surgery. Four studies concluded that the addition of OBS to hysterectomy was cost-effective for OC prevention in the general population. Similarly, OBS was cost-effective as an alternative to sterilisation via laparoscopy (four studies) or at caesarean section (two studies). However, given the paucity of high-quality long-term outcome data, the uncertainty of level of risk-reduction, lack of disutility data, there remains some uncertainty around cost-effectiveness.Conclusion This systematic review confirms that RRM/RRSO are cost-effective, and RRESDO is potentially cost-effective in women at intermediate/high risk of BC/OC in several high-income countries. Although OBS seems to be a potentially cost-effective option for OC risk-reduction, there is a need for high-quality evidence around its long-term including oncological outcomes. %U https://ijgc.bmj.com/content/ijgc/32/Suppl_2/A383.2.full.pdf